CY1109416T1 - Συμπυκνωμενες ετεροκυκλικες ενωσεις ως ρυθμιστες υποδοχεα σεροτονινης - Google Patents

Συμπυκνωμενες ετεροκυκλικες ενωσεις ως ρυθμιστες υποδοχεα σεροτονινης

Info

Publication number
CY1109416T1
CY1109416T1 CY20091100428T CY091100428T CY1109416T1 CY 1109416 T1 CY1109416 T1 CY 1109416T1 CY 20091100428 T CY20091100428 T CY 20091100428T CY 091100428 T CY091100428 T CY 091100428T CY 1109416 T1 CY1109416 T1 CY 1109416T1
Authority
CY
Cyprus
Prior art keywords
serotonin
heterocyclic compounds
concentrated
regulatory receptors
concentrated heterocyclic
Prior art date
Application number
CY20091100428T
Other languages
English (en)
Inventor
Nicholas I Carruthers
Wenying Chai
Xiaohu Deng
Curt A Dvorak
Annette K Kwok
Jimmy T Liang
Neelakandha Mani
Dale A Rudolph
Victoria D Wong
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34526458&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109416(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1109416T1 publication Critical patent/CY1109416T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ορισμένες συμπυκνωμένες ετεροκυκλικές ενώσεις που περιέχουν πυρρόλιο και πυραζόλιο είναι ρυθμιστές σεροτονίνης χρήσιμοι για τη θεραπεία ασθενειών στις οποίες μεσολαβεί σεροτονίνη.
CY20091100428T 2003-09-17 2009-04-10 Συμπυκνωμενες ετεροκυκλικες ενωσεις ως ρυθμιστες υποδοχεα σεροτονινης CY1109416T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50452803P 2003-09-17 2003-09-17
US55267304P 2004-03-11 2004-03-11
EP04816874A EP1668014B1 (en) 2003-09-17 2004-09-15 Fused heterocyclic compounds as serotonin receptor modulators

Publications (1)

Publication Number Publication Date
CY1109416T1 true CY1109416T1 (el) 2014-08-13

Family

ID=34526458

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100428T CY1109416T1 (el) 2003-09-17 2009-04-10 Συμπυκνωμενες ετεροκυκλικες ενωσεις ως ρυθμιστες υποδοχεα σεροτονινης

Country Status (30)

Country Link
US (5) US7402680B2 (el)
EP (1) EP1668014B1 (el)
JP (1) JP5069907B2 (el)
KR (1) KR101151653B1 (el)
CN (1) CN103788089A (el)
AR (1) AR047218A1 (el)
AT (1) ATE420881T1 (el)
AU (1) AU2004283196B2 (el)
BR (1) BRPI0414541B8 (el)
CA (1) CA2539426C (el)
CL (1) CL2009000943A1 (el)
CR (1) CR8302A (el)
CY (1) CY1109416T1 (el)
DE (1) DE602004019118D1 (el)
DK (1) DK1668014T3 (el)
EA (2) EA200801812A1 (el)
EC (1) ECSP066436A (el)
ES (1) ES2319539T3 (el)
HK (1) HK1118550A1 (el)
IL (2) IL174283A (el)
IS (1) IS2756B (el)
MX (1) MXPA06003150A (el)
NI (1) NI200600094A (el)
NZ (1) NZ545836A (el)
PL (1) PL1668014T3 (el)
PT (1) PT1668014E (el)
SG (1) SG146683A1 (el)
SI (1) SI1668014T1 (el)
TW (1) TWI345565B (el)
WO (1) WO2005040169A2 (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319539T3 (es) * 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
EP1716867A4 (en) * 2004-02-20 2009-09-23 Astellas Pharma Inc PRENENT AGENTS FOR MIGRAINE
CA2565683C (en) * 2004-06-30 2013-04-02 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
US20080171788A1 (en) * 2005-02-08 2008-07-17 Shinobu Akuzawa Medicament For Irritable Bowel Syndrome
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
ATE539753T1 (de) * 2005-08-04 2012-01-15 Janssen Pharmaceutica Nv Pyrimidin-verbindungen als serotonin-rezeptor- modulatoren
EP1923387B1 (en) * 2005-08-08 2011-10-19 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
RU2434872C2 (ru) * 2006-01-19 2011-11-27 Атерсис, Инк. Тиофенильные и пирролильные азепины в качестве лигандов серотонинового 5-ht2c рецептора и их применение
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
CN101479252B (zh) * 2006-05-05 2014-01-29 詹森药业有限公司 用于制备含吡唑的化合物的方法
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
WO2009058810A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica N.V. Process for the preparation of substituted 2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene derivatives
EP2229361A1 (en) * 2008-01-03 2010-09-22 Allergan, Inc. Tetrahydroindoles having sphingosine-1-phosphate receptor activity
WO2010053825A1 (en) 2008-10-29 2010-05-14 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
PT2358714E (pt) 2008-11-18 2012-10-09 Hoffmann La Roche Éteres de alquilciclo-hexilo de di-hidrotetraazabenzoazulenos
US8309578B2 (en) * 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
US8492374B2 (en) * 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
ES2574414T3 (es) 2011-04-21 2016-06-17 Basf Se Compuestos de pirazol pesticidas novedosos
EP2755974A1 (en) 2011-09-14 2014-07-23 Proximagen Limited New enzyme inhibitor compounds
WO2013156318A1 (en) 2012-04-16 2013-10-24 Basf Se Substituted pesticidal pyrazole compounds
BR122019015104B1 (pt) 2012-06-20 2020-04-07 Basf Se mistura pesticida, composição, composição agrícola, métodos para o combate ou controle das pragas de invertebrados, para a proteção dos vegetais em crescimento ou dos materias de propagação vegetal, para a proteção de material de propagação vegetal e uso de uma mistura pesticida
MX2015002039A (es) * 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirrolopirazoles como bloqueadores del canal de calcio tipo n.
WO2014063942A1 (en) 2012-10-23 2014-05-01 Basf Se Substituted pesticidal pyrazole compounds
JP2016503808A (ja) 2012-12-21 2016-02-08 エイビーティー ホールディング カンパニー セロトニン５−ＨＴ２ｃ受容体リガンドとしてのベンザゼピンおよびその使用
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2015055497A1 (en) 2013-10-16 2015-04-23 Basf Se Substituted pesticidal pyrazole compounds
AU2015349687B2 (en) * 2014-11-21 2020-07-09 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
JP2018510135A (ja) * 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
CN105503647A (zh) * 2015-12-10 2016-04-20 苏州昊帆生物科技有限公司 环丙基肼盐酸盐的制备方法
WO2017175045A1 (en) * 2016-04-08 2017-10-12 The Hong Kong Polytechnic University Pyrimidines for treatment of bacterial infections
KR101917264B1 (ko) 2016-12-22 2018-11-13 한국과학기술연구원 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2019137995A1 (en) 2018-01-11 2019-07-18 Basf Se Novel pyridazine compounds for controlling invertebrate pests
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) * 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
US3312716A (en) * 1964-08-11 1967-04-04 Aldrich Chem Co Inc 4-hydroxy-3-pyrrolidinemethanols
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1484140A (en) 1974-04-24 1977-08-24 Wyeth John & Brother Ltd Pyrrolopyridine derivatives
US3969355A (en) * 1974-11-01 1976-07-13 Morton-Norwich Products, Inc. 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
JPH03148265A (ja) 1989-11-01 1991-06-25 Sumitomo Chem Co Ltd ５，７―ジフェニル―４，６―ジアザインダン誘導体、その製造法およびそれを有効成分とする除草剤
US5137890A (en) * 1990-02-14 1992-08-11 Ortho Pharmaceutical Corporation 4-phenyl tetrahydropyrido(4,3-d)pyrimidines
US5053508A (en) 1990-03-09 1991-10-01 American Home Products Corporation Fused heterotricyclic imides with psychotropic activity and intermedrates thereof
US5648352A (en) 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
DK0638071T3 (da) 1992-12-28 1997-10-27 Eisai Co Ltd Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR)
US6677310B1 (en) 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US5843912A (en) 1994-07-06 1998-12-01 Universy Of Maryland Ring-expanded nucleosides and nucleotides
US5405848A (en) * 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
ES2223049T3 (es) 1994-04-29 2005-02-16 Pfizer Inc. Amidas aciclicas y ciclicas novedosas como estimuladores de la liberacion de neurotransmisores.
JPH11503757A (ja) 1995-04-18 1999-03-30 イーライ・リリー・アンド・カンパニー ５−ｈｔ▲下７▼レセプターにおいて生理学的および病理学的機能を生じるエルゴリン化合物の使用方法
EP0883613A1 (en) 1996-02-09 1998-12-16 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
TW470745B (en) * 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6025367A (en) * 1996-06-25 2000-02-15 Smithkline Beecham Plc Sulfonamide derivatives as 5HT7 receptor antagonists
JP4076234B2 (ja) * 1996-06-28 2008-04-16 明治製菓株式会社 テトラヒドロベンズインドール化合物
GB9700899D0 (en) 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
EP0905136A1 (en) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
US5951518A (en) 1997-10-31 1999-09-14 Teleflex, Incorporated Introducing device with flared sheath end
AU1558899A (en) 1997-11-10 1999-05-31 F. Hoffmann-La Roche Ag Isoquinoline derivatives for use against cns disorders
KR20010042904A (ko) * 1998-04-22 2001-05-25 기따자또 이찌로 광학 활성 테트라하이드로벤즈인돌 유도체
BR9911049A (pt) 1998-05-22 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de depressão resistente
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6245785B1 (en) 1998-11-30 2001-06-12 Warner Lambert Company Dissolution of triprolidine hydrochloride
GB9828004D0 (en) 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
GB9906624D0 (en) 1999-03-23 1999-05-19 Smithkline Beecham Plc Novel compounds
WO2000059510A1 (en) * 1999-04-01 2000-10-12 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
DE60008550T2 (de) 1999-09-09 2004-08-05 Kumiai Chemical Industry Co., Ltd. Pyrimidinderivate und herbizide welche diese enthalten
AU1025601A (en) 1999-10-18 2001-04-30 Smithkline Beecham Plc Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
JP2003522178A (ja) 2000-02-04 2003-07-22 ワイス ピロロイソキノリンおよびテトラヒドロピロロイソキノリン誘導体ならびに５−ｈｔ７受容体の媒介物質としてのそれらの使用
EP1264820A4 (en) 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co amide compounds
US6586469B2 (en) 2000-07-25 2003-07-01 Medpointe Healthcare Inc. Antihistaminic/antitussive compositions
ES2281434T3 (es) 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
CA2421493A1 (en) * 2000-09-06 2002-03-14 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies using substituted pyrazoles
US20040267010A1 (en) 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
AU2002244717B2 (en) * 2001-02-21 2007-07-19 Janssen Pharmaceutica N.V. Isoxazoline derivatives as anti-depressants
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US6559174B2 (en) 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6806380B2 (en) * 2001-10-02 2004-10-19 Lexicon Pharmaceuticals, Inc. Modified safe and efficient process for the environmentally friendly synthesis of imidoesters
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
US20030199542A1 (en) 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030199544A1 (en) 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
HRP20020452A2 (en) 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
RU2004138819A (ru) * 2002-05-30 2005-06-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ jak и cdk2
CA2490638C (en) * 2002-06-20 2008-01-22 H. Lundbeck A/S Combination therapy wherein a serotonin reuptake inhibitor is used
AU2003244632A1 (en) 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
WO2004011467A1 (ja) 2002-07-29 2004-02-05 Hokko Chemical Industry Co., Ltd. トリアゾロピリミジン誘導体および農園芸用殺菌剤
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003274050A1 (en) 2002-10-30 2004-05-25 Ciba Specialty Chemicals Holding Inc. Electroluminescent device
EP1592772A2 (en) * 2003-01-31 2005-11-09 Pfizer Products Incorporated 5ht7 antagonists and inverse agonists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0316128D0 (en) 2003-07-10 2003-08-13 Univ Aston Novel sulfonamide compounds
AU2004259009A1 (en) 2003-07-23 2005-02-03 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
ES2319539T3 (es) 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
JP2007506787A (ja) * 2003-09-23 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとしてのピラゾロピロール誘導体
KR20060076319A (ko) 2003-09-24 2006-07-04 콤비네이토릭스, 인코포레이티드 약물 조합들을 투여하는 치료 요법
JP2007513896A (ja) 2003-12-15 2007-05-31 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20090227562A1 (en) 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
US20060037652A1 (en) 2004-08-23 2006-02-23 Ranco Incorporated Of Delaware Reversing valve assembly with improved pilot valve mounting structure
CA2592353A1 (en) 2004-12-17 2006-06-22 Janssen Pharmaceutica, N.V. Tetrahydroisoquinoline compounds for treatment of cns disorders
WO2006138604A1 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders
EP1899334B1 (en) * 2005-06-17 2008-09-24 Janssen Pharmaceutica N.V. Naphthyridine compounds
ATE539753T1 (de) 2005-08-04 2012-01-15 Janssen Pharmaceutica Nv Pyrimidin-verbindungen als serotonin-rezeptor- modulatoren
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
AU2007225273A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
CN101479252B (zh) * 2006-05-05 2014-01-29 詹森药业有限公司 用于制备含吡唑的化合物的方法
JP2009544579A (ja) * 2006-06-29 2009-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換ベンジルアミン化合物
CN101511775A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 丁基和丁炔基苄基胺化合物
CN101511790A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 取代的氨基甲基苯甲酰胺化合物
US20080139564A1 (en) * 2006-11-16 2008-06-12 Keith John M Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators

Also Published As

Publication number Publication date
US20050119295A1 (en) 2005-06-02
HK1118550A1 (en) 2009-02-13
AU2004283196B2 (en) 2011-08-25
EP1668014B1 (en) 2009-01-14
IL174283A0 (en) 2006-08-01
AU2004283196A1 (en) 2005-05-06
JP5069907B2 (ja) 2012-11-07
NI200600094A (es) 2014-02-25
IL174283A (en) 2012-06-28
EA200600433A1 (ru) 2006-08-25
US8618288B2 (en) 2013-12-31
WO2005040169A3 (en) 2006-03-30
CA2539426C (en) 2012-07-10
TWI345565B (en) 2011-07-21
IS8348A (is) 2006-03-09
BRPI0414541A8 (pt) 2019-01-02
DK1668014T3 (da) 2009-04-20
US7579470B2 (en) 2009-08-25
US20100016281A1 (en) 2010-01-21
BRPI0414541A (pt) 2006-11-07
IS2756B (is) 2011-10-15
US7897771B2 (en) 2011-03-01
US20090270370A1 (en) 2009-10-29
BRPI0414541B1 (pt) 2019-02-26
CA2539426A1 (en) 2005-05-06
BRPI0414541B8 (pt) 2021-05-25
NZ545836A (en) 2009-09-25
CN103788089A (zh) 2014-05-14
ES2319539T3 (es) 2009-05-08
PL1668014T3 (pl) 2009-06-30
EA010905B1 (ru) 2008-12-30
EA200801812A1 (ru) 2009-06-30
KR20070023633A (ko) 2007-02-28
MXPA06003150A (es) 2006-08-31
KR101151653B1 (ko) 2012-06-28
SI1668014T1 (sl) 2009-06-30
ATE420881T1 (de) 2009-01-15
US20080103132A1 (en) 2008-05-01
JP2007505908A (ja) 2007-03-15
TW200521123A (en) 2005-07-01
SG146683A1 (en) 2008-10-30
PT1668014E (pt) 2009-03-17
DE602004019118D1 (de) 2009-03-05
WO2005040169A2 (en) 2005-05-06
US7402680B2 (en) 2008-07-22
CR8302A (es) 2008-09-10
IL209082A0 (en) 2011-01-31
US20110040088A1 (en) 2011-02-17
EP1668014A2 (en) 2006-06-14
CL2009000943A1 (es) 2009-08-21
AR047218A1 (es) 2006-01-11
ECSP066436A (es) 2006-09-18

Similar Documents

Publication Publication Date Title
CY1109416T1 (el) Συμπυκνωμενες ετεροκυκλικες ενωσεις ως ρυθμιστες υποδοχεα σεροτονινης
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
CY1112297T1 (el) Ετεροκυκλικοι αναστολεις της μεκ και μεθοδοι χρησης αυτων
DE602005017895D1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
ATE374610T1 (de) 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
CY1111670T1 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
PA8496301A1 (es) Inhibidores de metaloproteasas.
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
BRPI0518563A2 (pt) moduladores de delta-opiàide tricÍclicos
DK1685125T3 (da) Pyrrolderivater der er nyttige til behandlingen af proliferative sygdomme
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ATE486071T1 (de) Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors
DE60321722D1 (de) Derivate von aryl-chinazolin/aryl-2amino-phenyl-methanon zurförderung der freisetzung von parathormon
NO20045554L (no) Fremgangsmate for behandling av diabetes
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE399777T1 (de) Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu
IS7407A (is) Afleysing lausnarsambanda atorvastatínhálfkalsíums